Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2023)
Allogene Therapeutics (ALLO) posted Receivables - Other of $1.2 million for Q1 2023, down 20.0% sequentially from $1.5 million in Q4 2022, and down 87.23% YoY from $9.4 million in Q1 2022.
Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2023) Analysis & Trends
Allogene Therapeutics has reported Receivables - Other for 4 years, with the latest figure at $1.2 million in Q1 2023.
- Quarterly Receivables - Other fell 87.23% year-over-year to $1.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $1.2 million (down 87.23% YoY) and the FY2022 annual result came in at $1.5 million, down 63.41% from the prior year.
- Receivables - Other eased to $1.2 million in Q1 2023 per ALLO's latest filing, from $1.5 million in the prior quarter.
- Over five years, Receivables - Other peaked at $10.2 million in Q2 2022 and troughed at $1.2 million in Q1 2023.
- A 4-year average of $5.2 million and a median of $4.2 million in 2021 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2022 and 2023: Receivables - Other soared 142.86% in 2022, then slumped 87.23% in 2023.
- Over 4 years, Receivables - Other stood at $3.8 million in 2020, then advanced by 7.89% to $4.1 million in 2021, then slumped by 63.41% to $1.5 million in 2022, then slipped by 20.0% to $1.2 million in 2023.
- According to Business Quant data, Receivables - Other over the past three periods registered $1.2 million, $1.5 million, and $4.3 million for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.50 Mn |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.30 Mn |
| Jun 30, 2022 | 10.20 Mn |
| Jun 30, 2022 | 10.20 Mn |
| Mar 31, 2022 | 9.40 Mn |
| Mar 31, 2022 | 9.40 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Sep 30, 2021 | 9.30 Mn |
| Sep 30, 2021 | 9.30 Mn |
| Jun 30, 2021 | 4.20 Mn |
| Jun 30, 2021 | 4.20 Mn |
| Mar 31, 2021 | 4.50 Mn |
| Mar 31, 2021 | 4.50 Mn |
| Dec 31, 2020 | 3.80 Mn |
| Dec 31, 2020 | 3.80 Mn |